##### Dr Jennifer S Lees

*MA (Cantab) MBChB MRCP (Neph) PhD FERA*

*Curriculum Vitae*

**Current positions**

* 2024-present: Wellcome Trust Early Career Fellow (University of Glasgow) and Honorary Consultant Nephrologist (NHS Greater Glasgow and Clyde)
* 2025-present: Deputy Director of Research, School of Cardiovascular and Metabolic Health, University of Glasgow

**GMC registration** 2009-present:Registered with a licence to practice (GMC #7041214)

2022-present: Specialty register for Renal and General Internal Medicine

In my current employment, 80% of my time is dedicated to academic work, which is primarily research, with a smaller component for teaching and supporting professional activities. As Honorary Consultant Nephrologist (NHS Greater Glasgow and Clyde; 2022-present), I spend 20% of my time contributing to a regional nephrology service, providing inpatient, outpatient and emergency care.

## Education and qualifications

* 2022: Certificate of Completion of Training (CCT) – Nephrology and General Internal Medicine
* 2020: Doctor of Philosophy (PhD) – Medicine: University of Glasgow
* 2019: Specialty Certificate Examination (SCE) – Nephrology: Royal College of Physicians
* 2012: Member of the Royal College of Physicians (MRCP): Royal College of Physicians
* 2010: Master of Arts (MA; Cantab): University of Cambridge
* 2009: Bachelor of Medicine Bachelor of Surgery (MBChB): University of Edinburgh
* 2006: Bachelor of Arts (BA; Hons): University of Cambridge

## Employment history

* 2022-2024: Post-CCT Senior Clinical Research Fellow in Renal Medicine (University of Glasgow) and Honorary Consultant Nephrologist (NHS Greater Glasgow and Clyde)
* 2020-2022: Chief Scientist Office Scotland Postdoctoral Clinical Lecturer in Renal Medicine (University of Glasgow) and Honorary Specialty Registrar in Nephrology/General Internal Medicine – West of Scotland
* 2019-2020: Specialty Registrar in Nephrology and General Internal Medicine – West of Scotland
* 2016-2019: Out of programme research experience: PhD at the University of Glasgow
* 2013-2016: Specialty Registrar in Nephrology and General Internal Medicine – West of Scotland
* 2011-2013: Core Medical Training – South-East Scotland
* 2009-2011: Academic Foundation Training – South-East Scotland

**Grants and research funding**

**Personal fellowships** *– awarded to self*

* 2024-2029: Wellcome Trust Early Career Award (301005/Z/23/Z): £1,119,039. “Kidney function as a complicator of cancer treatment”
* 2020-2022: NHS Education for Scotland/Chief Scientist Office Postdoctoral Lectureship Scheme (PCL/20/10): salary + £20,000 consumables. “Defining the bi-directional relationship between cancer and kidney disease”
* 2017-2019: Kidney Research UK Training Fellowship (TF\_013\_20161125): £171,115. “Vitamin K in Transplanted kidney Organ Recipients: Investigating vEssel Stiffness (ViKTORIES)”
* 2016-2017: British Heart Foundation Centre of Research Excellence Award (RE/13/5/30177): salary + £30,000 consumables.

**Principal investigator project grants** - *awarded to self*

* 2024-2025: Karolinska Institutet Research Foundation Grants (2024-02610): SEK 282,800. “The role of kidney function in cancer treatment eligibility and clinical outcomes”.
* 2007-2012: 10 project/travel grants during undergraduate/early postgraduate career: total £11,115.

**Co-investigator project grants** - *awarded to collaborators*

* 2025: Chief Scientist Office Health Improvement, Protection and Services Research Grant (HIPS/24/31): £349,802. **“Scottish Cardiometabolic Assessment and Risk Determination: SCOTCARD”.**
* 2024-2026: International Society of Nephrology, Clinical Research Programme: USD 19,988. “Cystatin C in Africa: CKD screening, diagnosis, and predicting outcomes”.
* 2024-2025: Kidney Research UK Project Grant (RP\_015\_20221129): £80,869. “Kidney-related adverse events associated with intravitreal VEGF-inhibitor use: a national cohort Study”.
* 2022-2023: USyd-UofG Partnership Award: AUD 30,539. “Sex and Health; Evaluating diagnosis, Risk factOrs and Complications in chronic Kidney diSease (SHE-ROCKS)”.

## Selected trials experience

* 2025-present: Steering Committee UK, IMPEDE-PKD trial (NCT04939935)
* 2024-present: Principal Investigator (Glasgow), SYNCHRONIZE-CVOT (Boehringer Ingelheim)
* 2019-present: UK Renal Trials Network member
* 2017-2019: Chief Investigator (ViKTORIES; ISRCTN22012044; funded Kidney Research UK). Published: **Lees JS** et al, Am J Transplant (2021); doi:10.1111/ajt.16566
* 2016-2019: Co-investigator (K4Kidneys; ISRCTN21444964; funded British Heart Foundation). Published: Witham MD, **Lees JS**, et al. J Am Soc Nephrol (2020); 31(10): 2434-2445

**Research accreditation**

* Office for National Statistics Accredited Researcher #40534
* Current valid Good Clinical Practice certificate and MRC Research, GDPR and Confidentiality training

## Selected professional activities

## International

* 2024-present: Elected Ordinary Member, European Renal Association Council
* 2023-2024: International Mentor for European Renal Association Young Nephrologists’ Platform
* 2023-present: Biomarkers/Formulas Editor, Nephrology Dialysis Transplantation
* 2019-present: Graphical Abstracts Editor, Nephrology Dialysis Transplantation

**Local**

* 2025-present: Deputy Director of Research, School of Cardiovascular and Metabolic Health, U of G
* 2023-2025: Lead for Data Science, School of Cardiovascular and Metabolic Health, U of G
* 2023-present: Patient and Public Involvement and Engagement (PPIE) steering committee, College of Medical and Veterinary Life Science, University of Glasgow
* 2021-present: Lead for West of Scotland Kidney Research PPIE Group

**Peer review including grants**

* Manuscript peer review for respected medical journals, including Nature Medicine, New England Journal of Medicine, The BMJ and The Lancet.
* International and national grant reviews on behalf of UK Research and Innovation: Medical Research Council, Barts Charity UK, Kidney Research UK, the Danish Heart Foundation.

**Selected international invited seminars and presentations**

* 2025: International Society of Nephrology Webinar: Innovative trial designs and generalizability in clinical research – “Generalizability and gender issues in clinical trials”
* 2025: European Renal Association Annual Congress (Vienna) - “State of the art and future directions for managing atherosclerotic vascular disease in CKD”
* 2025: European Renal Association Education meeting (Lisbon): “How to assess kidney function and diagnose CKD”
* 2024: International Society of Nephrology PARADIGM Consensus Meeting (Vancouver): “Reconsidering clinical trials based on single targets or thresholds: appreciating individual variability”
* 2024: European Renal Association Annual Congress (Stockholm): “The role of eGFR slope analyses in trials: an update”
* 2023: World Congress of Nephrology (Bangkok): Women in Nephrology “Rising Stars in Nephrology” session - “Cystatin C in Chronic Kidney Disease”
* 2023: European Society of Hypertension (Milan/Hybrid): “GFR, Cystatin C and Cardiovascular Disease in CKD”
* 2023: Pre-hypertension, Hypertension and Cardiometabolic Syndrome (Prague/Hybrid): “GFR, Cystatin C and Cardiovascular Disease in CKD”

**Selected prizes, honours and awards**

* 2024: Fellow of the European Renal Association
* 2022: Eberhard-Ritz Award: Young Investigator Award for Clinical Science, European Renal Association
* 2022: Raine Award, UK Kidney Association
* 2022: University of Glasgow “People Make Research: CAREERS” – recognized by University of Glasgow colleagues for making a positive difference to their career journey

**Publications and other academic outputs**

* **Publications:** 87 (31% first author; 25% corresponding author; 18% last author)
* **H-index:** Web of Science 20, Google Scholar 23.
* **ORCiD:** <https://orcid.org/0000-0001-6331-0178>
* **Highest Altmetrics scores:** 810\*\*\* (ref #25), 808\*\* (ref #22), 167\*(ref #13)

**Most significant publications**

* **Lees JS**, Welsh CE, Celis-Morales C, et al. “Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease”. Nature Medicine (2019): 25; 1753-1760. Author correction: Nat Med (2020); 26(8): 1308.

This paper triggered my enthusiasm for epidemiology. We showed that cystatin C accurately classifies patients with CKD into high-risk groups for cardiovascular disease, offering opportunities for primary prevention (to >1.5% of the general population). Follow-up work by the international epidemiology organisation CKD Prognosis Consortium (<https://doi.org/10.1001/jama.2023.17002>; *Lees JS contributing author*) has influenced international guidance on CKD diagnosis and management.

I co-designed, led and wrote this paper. I did not perform the analysis, but I gained valuable experience in epidemiology. This paper also shows a dedication to research integrity: post-publication, I became aware internally of a coding error with minor implications for the results of the published work. I alerted the editors at Nature Medicine and arranged for the work to be corrected.

* **Lees JS**, Fu EL, Faucon A, et al. “Accuracy of glomerular filtration rate estimates among patients with cancer”. Br J Cancer (2025) [in press]

This is the first output from my Wellcome fellowship, significant as: i) the subject matter provides the rationale and pilot work for objective 3 in the current research application; and ii) it provides evidence that I have recently initiated and led a project collaborating with colleagues across specialties (nephrology, oncology, epidemiology) and across institutions (University of Glasgow, Tufts University, Karolinska Institutet) relevant to the delivery of the current research proposal.

* **Lees JS**, Rankin AJ, Gillis KA, et al. “The ViKTORIES trial: a randomised, double-blind, placebo-controlled trial of vitamin K supplementation to improve vascular health in kidney transplant recipients”. Am J Transplant (2021); 21(10): 3356-3368

This is the report of the primary output of my PhD, where I was the chief investigator on this single-centre trial. Though the result was neutral, this work gave me important insights into trial design and conduct, equity of access, barriers to implementation, interpretation and generalisability: invaluable for the planned research programme.

**Primary research publications**

1. Dawson J, **Lees JS**, Chang T-P, Walters MR, Ali M, David SM, Diener H-C, Lees KR and for the GAIN and VISTA Investigators. “Association between disability measures and healthcare costs after initial treatment for acute stroke”. Stroke (2007); 38(6): 1893-1898
2. Quinn TJ, Dawson J, **Lees JS**, ChangTP, Walters MR, Lees KR, and for the GAIN and VISTA investigators. “Time spent at home post stroke: “Home-time” - a meaningful and robust outcome measure for stroke trials”. Stroke (2008); 39(1): 231-233
3. **Lees JS,** Mishra NK, Saini M, Lyden PD, Shuaib A. “Low body temperature does not significantly compromise therapeutic effect of alteplase”. Stroke (2011); 42(9): 2618-2621
4. **Lees JS,** Sena ES, Egan K, et al. “Stem cell-based therapy for experimental stroke: a systematic review and meta-analysis”. Int J Stroke (2012); 7(7): 582-528
5. Antonic A, Sena ES, **Lees JS**, et al. “Stem cell transplantation in traumatic spinal cord injury: a systematic review and meta-analysis of animal studies.” PLoS Biol (2013); 11(12) e1001738
6. **Lees JS,** McQuarrie EP, Mordi N, et al. “Risk factors for bleeding complications after nephrologist-performed native renal biopsy”. Clin Kidney J (2017); 10(4): 573-577
7. Stoumpos S, **Lees J**, Welsh P, et al. “The utility of anti-Mullerian hormone in women with chronic kidney disease, on haemodialysis and after kidney transplantation”. Reprod Biomed Online (2018); 36(2): 219-226
8. Gillis KA, **Lees JS**, Ralston MR, et al. “Interaction between socioeconomic deprivation and likelihood of pre-emptive transplantation: influence of competing risks and referral characteristics – a retrospective study”. Transpl Int (2018); https://doi.org/10.1111/tri.13336
9. **Lees JS,** Findlay M, Mark PB, Geddes CC. “The impact of coronary angiography on renal transplant function”. QJM (2018); 112(1): 23-27
10. Elyan BMP, **Lees JS,** Gillis KA, et al. “Obesity is not associated with progression to end stage renal disease in patients with biopsy-proven glomerular diseases”. BMC Nephrol (2019); 20(1): 237
11. Grant CH, Gillis KA, **Lees JS,** et al. “Proton pump inhibitor use and progression to major adverse renal events: a competing risk analysis”. QJM (2019); <https://doi.org/10.1093/qjmed/hcz166>
12. **Lees JS,** Chapman FA, Witham MD, Jardine AG, Mark PB. “Vitamin K status, supplementation and vascular disease: a systematic review and meta-analysis”. Heart (2019); 105(12): 938-945
13. **\*Lees JS**, Welsh CE, Celis-Morales C, et al. “Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease”. Nat Med (2019): 25; 1753-1760. Author correction: Nat Med (2020); 26(8): 1308.
14. **Lees JS**, Mangion K, Rutherford E, et al. “Vitamin K for kidney transplant organ recipients: investigating vessel stiffness (ViKTORIES): study rationale and protocol of a randomised controlled trial”. Open Heart (2020); 7: e001070. https://doi.org/10.1136/openhrt-2019-001070
15. Witham MD, **Lees JS**, White M, et al. “Vitamin K supplementation to improve vascular stiffness in chronic kidney disease - the K4Kidneys randomised controlled trial”. J Am Soc Nephrol (2020); 31(10): 2434-2445
16. Rankin AJ, Zhu L, Mangion K, et al **(Lees JS, middle author)**. “Global longitudinal strain by feature-tracking cardiovascular magnetic resonance imaging predicts mortality in patients with end-stage kidney disease”. Clin Kidney J (2021); 14(10): 2187-2196
17. O’Sullivan E, **Lees JS**, Howie KL, et al. “Prolonged SARS-CoV-2 viral shedding in patients with chronic kidney disease”. Nephrology (2021); 26 (4): 328.322
18. **Lees JS**, Rankin AJ, Gillis KA, et al. “The ViKTORIES trial: a randomised, double-blind, placebo-controlled trial of vitamin K supplementation to improve vascular health in kidney transplant recipients”. Am J Transplant (2021); 21(10): 3356-3368
19. Sullivan M, Jani B, **Lees JS**, et al. “Multimorbidity and the risk of major adverse kidney events: findings from the UK Biobank cohort”. Clin Kidney J (2021); 14(11): 2409-2419
20. Li KK, Woo YM, Stirrup O, et al **(Lees JS, middle author)**. “Genetic epidemiology of SARS-CoV-2 transmission in renal dialysis units – a high risk community-hospital interface.” J Infection (2021); 83(1): 96-103
21. Edy E, Rankin AJ, **Lees JS**, et al. “Cardiovascular MRI for the detection of thoracic aorta calcification in patients with end-stage renal disease”. J Cardiovasc Magn Reson (2021); 23(1): 85
22. **\*\*Lees JS,** Ho F, Parra-Soto S, et al. “Kidney function and cancer risk: an analysis using creatinine and cystatin C in a cohort study”. EClinicalMedicine (2021); 38: 101030
23. Sullivan MK, **Lees JS,** Drake TM, et al. “Acute kidney injury in patients hospitalised with COVID-19 from the ISARIOC WHO CCP-UK Study”. Nephrol Dial Transplant (2021) [online ahead of print]
24. Rankin AJ, Mangion K, **Lees JS,** et al. “Myocardial changes on 3T cardiovascular magnetic resonance imaging in response to haemodialysis with fluid removal”. J Cardiovasc Magn Reson (2021); 23(1): 125
25. **\*\*\***Sullivan MK, Jani B, Rutherford E, et al. (**Lees JS, senior author).** “Potential impact of NICE guidelines on referrals from primary care to nephrology”. Br J Gen Practice (2022); 73(727): e141-147
26. Morrow AJ, Sykes R, McIntosh A, et al **(consortium member).** “A multi-system cardio-renal investigation of post-COVID-19 illness. Nat Med (2022); 28(6): 1303-1313.
27. Mayne KJ, Shemilt R, Keane DF, **Lees JS (joint senior author)**, Mark PB, Herrington WG. “Bioimpedance indices of fluid overload and cardiorenal outcomes in heart failure and chronic kidney disease: a systematic review”. J Card Fail (2022) 28(11):1628-1641. https://doi.org/10.1016/j.cardfail.2022.08.005
28. **Lees JS**, Hanlon P, Butterly E, et al. “The impact of age, sex and morbidity count on trial attrition: a meta-analysis of individual participant-level data from phase 3/4 industry-funded clinical trials”. BMJ Medicine (2022) 1(1): e000217
29. **Lees JS**, Rutherford E, Stevens KI, et al. “Assessment of Cystatin C for risk stratification in adults with chronic kidney disease”. JAMA Netw Open (2022); 5(1): e2238300
30. Mayne KJ, **Lees JS**, Rutherford E et al. “Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios: associations with mortality in a haemodialysis cohort.” Clin Kidney J (2022) 16(3): 512-520
31. Mayne KJ, Shemilt R, Kean DF, et al **(Lees JS**, **joint senior author)**. “Bioimpedance indices of fluid overload and cardiorenal outcomes in heart failure and chronic kidney disease: a systematic review”. J Card Fail (2022) 29(11): 1628-1641
32. Lithgow H, Johnston L, Ho FK et al **(Lees JS, middle author).** “Protocol for a randomised controlled trial to investigate the effects of vitamin K2 on recovery from muscle damaging resistance exercise in young and older adults – the TAKEOVER study.” Trials (2022) 23(1): 1026
33. Chen DC, **Lees JS**, Lu K et al. “Differential associations of cystatin C versus creatinine based kidney function with risks of cardiovascular event and mortality among South Asian individuals in the UK Biobank”. J Am Heart Assoc (2022) 12(3): e027079
34. **Lees JS**, De La Mata N, Sullivan MK et al. “Sex differences in associations between creatinine and cystatin C-based kidney function measures with stroke and major bleeding”. European Stroke Journal (2023); 8(3): 756-768
35. Mangion K, Morrow AJ, Sykes R et al **(Lees JS, consortium member).** “Post-COVID-19 illness and associations with sex and gender”. BMA Cardiovasc Disord (2023); 23(1): 389
36. McGovern D, **Lees JS,** Traynor JP et al. “Outcome in ANCA-associated vasculitis in Scotland: validation of the renal risk score in a complete national cohort”. Kidney International Reports (2023); 8(8): 1648-1656
37. Grams ME, Coresh J, Matsushita K et al **(Lees JS, middle author).** “Estimated glomerular filtration rate, albuminuria and adverse outcomes: an individual participant meta-analysis”. Journal of the American Medical Association (2023) 330(13): 1266-1277.
38. Jani BD, Sullivan MK, Hanlon P et al **(Lees JS, middle author)**. “Personalised Lung Cancer Risk Stratification and Lung Cancer Screening: Do General Practice Electronic Medical Records have a Role?”. British Journal of Cancer (2023) 129(12): 1968-1977
39. **Lees JS**, Dobbin SJH, Elyan BMP, et al. “A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.” Nephrol Dial Transplant (2023) 38(7): 1666-1681
40. Elyan BMP, Rankin S, Jones R, Lang NN, Mark PB, **Lees JS (senior author)**. “Kidney Disease Patient Representation in Trials of Combination Therapy With VEGF-Signaling Pathway Inhibitors and Immune Checkpoint Inhibitors: A Systematic Review”. Kidney Medicine (2023) 5(7): 100672
41. Rankin S, Elyan BMP, Jones RC et al **(Lees JS, middle author)**. “Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitor trials”. JACC Cardio-Oncology 2024: https://doi.org/[10.1016/j.jaccao.2023.12.010](https://doi.org/10.1016/j.jaccao.2023.12.010)
42. Mayne KJ, Staplin N, Keane D et al (**Lees JS, middle author**). “Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease”. J Am Soc Nephrol (2024) 35(2):202-215. <https://doi.org/10.1681/ASN.0000000000000271>
43. Bate S, McGovern D, Costigliolo F et al (**Lees JS, middle author**). “The Improved Kidney Risk Score in ANCA Vasculitis for Clinical Practice and Trials”. J Am Soc Nephrol (2024) 35(3):335-346. <https://doi.org/10.1681/ASN.0000000000000274>
44. Shemilt R, Sullivan MK, Hanlon P et al **(Lees JS, senior author).** “Sex differences in the diagnosis of advanced cancer and subsequent outcome across the range of eGFR”. Nephrol Dial Transplant (2024) 39(11): 1799-1808; <https://doi.org/10.1093/ndt/gfae059>
45. Chen DC, Lu K, Scherzer R, **Lees JS** et al. “Cystatin C and Creatinine-based estimated GFR differences: prevalence and predictors in the UK Biobank”. Kidney Medicine (2024): 6(4); 100796s
46. **Lees JS**, Crowther J, Hanlon P et al. “Participant characteristics and exclusion from trials: a meta-analysis of individual participant-level data from phase 3/4 industry-funded trials in chronic medical conditions”. BMJ Medicine (2024) 3(1): e000732; <https://doi.org/10.1136/bmjmed-2023-000732>
47. Sullivan MK, **Lees JS**, Rosales BM et al. “Sex and the relationship between cardiometabolic risk factors and estimated GFR decline: a population-based cohort study”. Am J Kidney Dis (2024); <https://doi.org/10.1053/j.ajkd.2024.05.007>
48. Liu Q, Celis-Morales C, **Lees JS** et al. “Change in physical activity and its association with decline in kidney function: A UK Biobank-based cohort study”. J Cachexia Sarcopenia Muscle (2024); 15(5): 2046-2055. <https://doi.org/10.1002/jcsm.13551>
49. Elyan BMP, Sullivan MK, Hedley J et al (**Lees JS, senior author**). “The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysis.” BJC Reports (2024); <https://doi.org/10.1038/s44276-024-00081-7>
50. Marshall W, Curran G, Traynor JP et al (**Lees JS, senior author**). “Sodium zirconium cyclosilicate treatment and rates of emergency interventions for hyperkalaemia: a propensity-score weighted case-control study”. Clin Kidney J (2024): [https://doi.org/10.1093/ckj/sfae313](https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.org%2F10.1093%2Fckj%2Fsfae313&data=05%7C02%7CJennifer.Lees%40glasgow.ac.uk%7C09c5b8d8ed1c4efce6a908dd46e02266%7C6e725c29763a4f5081f22e254f0133c8%7C1%7C0%7C638744650648541046%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=nfw4PzkPchbsnYeM5T2j%2B%2FV7Z5fuemYOL%2BMamD3B1n0%3D&reserved=0)
51. Liu Q, Celis-Morales C, **Lees JS** et al. “Effect of exercise on kidney-relevant biomarkers in the general population: A systematic review and meta-analysis”. BMJ Open (2024): https://doi.org/10.1136/bmjopen-2024-093017
52. Liu Q, Welsh P, Celis-Morales C et al (**Lees JS, middle author**). “Discordance between Cystatin C-based and Creatinine-based estimated glomerular filtration rate and health outcomes in adults: a systematic review and meta-analysis”. Clin Kidney J (2025): 18(3); [https://doi.org/10.1093/ckj/sfaf003](https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.org%2F10.1093%2Fckj%2Fsfaf003&data=05%7C02%7CJennifer.Lees%40glasgow.ac.uk%7C09c5b8d8ed1c4efce6a908dd46e02266%7C6e725c29763a4f5081f22e254f0133c8%7C1%7C0%7C638744650648493272%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=0kWs33Igs%2FFa8Bp%2FsRqWUByIkD1KvcGANo9a%2BLPwKSs%3D&reserved=0)
53. Rochmawati I, Deo S, **Lees JS** et al. “Adding traditional and emerging biomarkers for risk assessment in secondary prevention: A prospective cohort study of 20,656 patients with cardiovascular disease”. European Journal of Preventative Cardiology (2025): <https://doi.org/10.1093/eurjpc/zwae352>
54. Ho F, Mark PB, **Lees JS** et al. “A proteomics-based approach for prediction of different cardiovascular diseases and dementia”. Circulation (2025); 151(5): 277-287. <https://doi.org/10.1161/CIRCULATIONAHA.124.070454>
55. Sykes R, Morrow AJ, Mangion K et al (**Lees JS, consortium author**). “Radiological abnormalities persist following COVID-19 and correlate with impaired health-related quality of life: a prospective study of hospitalised patients”. BMJ Open Respir Res (2025); 12(1): e001985. <https://doi.org/10.1136/bmjresp-2023-001985>
56. Elyan BMP, Tan B, Lambourg E, et al (**Lees JS, middle author**). “Incidence of cancer in people with CKD not requiring kidney replacement therapy: A systematic review and meta-analysis”. Clin Kidney J (2025): <https://doi.org/10.1093/ckj/sfaf084>
57. McChrystal R, **Lees JS**, Gillies K, et al. “Participant and trial characteristics reported in predictive analyses of trial attrition: An umbrella review of systematic reviews of randomised controlled trials across multiple conditions”. Trials (2025); <https://doi.org/10.1186/s13063-025-08794-x>
58. Liu Q, Celis-Morales C, **Lees JS**, et al. “Discordance between cystatin C-based and creatinine-based estimated glomerular filtration rate and mortality in general population: evidence from the UK Biobank”. Clin Chemistry (2025): <https://doi.org/10.1093/clinchem/hvaf063>
59. Mok Y, Surapaneni A, Sang Y et al (**Lees JS, senior author**). “Chronic kidney disease and incident cancer risk: an individual participant data meta-analysis”. Br J Cancer (2025) [in press]
60. Ishigami J, Surapaneni A, Matsushita K, et al (**Lees JS, middle author**). “Estimated glomerular filtration rate, albuminuria, and risk of infection: a collaborative meta-analysis of individual participant data”. EClinicalMedicine (2025) [in press]
61. Walker HJ, Carrero JJ, Sullivan MK et al (**Lees JS, middle author**). “Frailty in Adults with Chronic Kidney Disease and Validation of the Kidney Failure Risk Equation in Frailty Sub-Groups”. Clin J Am Soc Nephrol (2025): [https://doi.org/10.2215/CJN.0000000739](https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.org%2F10.2215%2FCJN.0000000739&data=05%7C02%7CJennifer.Lees%40glasgow.ac.uk%7C5f85d68c725e46126c3008ddd6661cc1%7C6e725c29763a4f5081f22e254f0133c8%7C1%7C0%7C638902456239133499%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=NgrWoZuqwzSl9X4oJ8mGqN6Tan2eccSSJNPyBFO%2BKgA%3D&reserved=0)
62. Mayne KJ, Walker H, Elyan BMP et al (**Lees JS, senior author**). “Cardiovascular-kidney-metabolic syndrome and mortality in a prospective UK cohort study”. Eur J Prevent Cardiol (2025) [in press]
63. **Lees JS**, Fu EL, Faucon A, et al. “Accuracy of glomerular filtration rate estimates among patients with cancer”. Br J Cancer (2025) [in press]
64. Estrella ME, Ballew SH, Sang Y et al (**Lees JS, middle author**). “Discordance in creatinine based eGFR and cystatin C based eGFR and clinical outcomes A meta-analysis”. JAMA (2025) [in press]
65. McChrystal R, Hanlon P, **Lees JS** et al. “Modelling rates of trial attrition: An analysis of individual participant data from 90 randomised controlled trials of pharmacological interventions for multiple conditions.” J Clin Epidemiol (2025) [in press]
66. Levin A, Jaure A, Little DJ et al (**Lees JS, middle author**). “Changing paradigms of studies in kidney disease”. Kidney Int (2025) [in press]
67. Mark PB, Stafford L, Grams ME et al (**Lees JS, joint senior author**). “Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis of the Global Burden of Disease Study 2023”. The Lancet (2025) [in press]

**Reviews**

1. **Lees JS,** Mark PB, Jardine AG. “Cardiovascular complications of chronic kidney disease.” Medicine (2015); 43 (8): 469-473.
2. **Lees JS,** Mark PB, Witham MD. “Vitamin K and vascular calcification” Curr Opin Nephrol Hypertens (2021); 30(4): 430-436
3. **Lees JS,** Elyan BMP, Herrmann SM, et al. “The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes”. Nephrol Dial Transplant (2023) 38(5): 1071-1079
4. Mayne KJ, **Lees JS**, Mark PB. “Cardiovascular complications of chronic kidney disease.” Medicine (2022).
5. Mayne KJ, **Lees JS**, Herrington WG. “Bioimpedance in CKD: an untapped resource?”. Nephrol Dial Transplant (2023) 38(3): 583-585
6. Grant CH, Salim E, **Lees JS,** Stevens KI. Deprivation and chronic kidney disease: a review of the evidence. Clin Kidney J (2023) 16(7): 1081-1091
7. Mayne KJ, Sullivan MK, **Lees JS (senior author). “**Sex and gender differences in the management of chronic kidney disease and hypertension”. Journal of Human Hypertension (2023) 37(8): 649-653
8. **Lees JS,** Fabian J and Shlipak MJ. “Cystatin C should be routinely available for estimating kidney function”. Curr Opin Nephrol Hypertension (2024): 33(3):337-343.
9. Mayne KJ, Hanlon P, **Lees JS (senior author)**. “Detecting and Managing the Patient with CKD in Primary Care: A Review of the Latest Guidelines”. Diabetes Obes Metab 2024: <http://dx.doi.org/10.1111/dom.15625>.

**Editorial/commentary**

1. **Lees JS**,McQuarrie EP,Mackinnon B.“Renal biopsy: it is time for pragmatism and consensus”.Clin Kidney J (2018); 11(5): 605-609
2. **Lees JS**, Mark PB. “Cystatin C to predict renal disease and cardiovascular risk”. Nephrol Dial Transplant (2020); 36 (1): 39-41
3. **Lees JS** and Mark PB**.** “Fruit for thought: lifestyle interventions to reduce the risk of future chronic kidney disease”. Nephrol Dial Transplant (2021); 36(6): 963-965
4. **Lees JS** and Mark PB. “Insights into vitamin K metabolism in chronic kidney disease: more complicated than kale deficiency”. Kidney Int (2022); 101(2): 216-219
5. **Lees JS** and Shlipak MG. “Age-adapted eGFR thresholds underestimate risks beyond kidney failure associated with CKD in older populations”. J Am Geriat Soc (2022) 70(12): 3660-3664
6. Stevens KI, Graham-Brown M, **Lees JS (senior author)**. “Let’s get physical: considering and overcoming the barriers to physical activity in CKD”. Nephrol Dial Transplant (2022) 38(6): 1405-1407
7. Stevens KI and **Lees JS (senior author).** “Measure and risk: Cystatin C, creatinine and controversy in CKD”. Nephrol Dial Transplant (2023) 38(8): 1785-1788
8. Radley A, **Lees JS**, Stevens KI. “Cardiovascular disease in older women with CKD”. Clin Kidney J (2023); 16(12): 2304-2308
9. **Lees JS** and Mark PB. “GFR slope as a surrogate marker for future kidney failure”. Nature Reviews Nephrology (2023) 19(10): 625-626

**Case reports**

1. **Lees JS**, Church N, Langdale-Brown B, Bellamy C, Gibson P, Watson S. “IgG4-related disease: a novel, important but easily missed condition.” J R Coll Physicians Edinb. (2013); 43(2): 126-33.
2. Groome C, Doak A, Stirling C, **Lees JS (senior author)**. “Under pressure”. Hypertension Journal (2023) 7(2): 99-102

## Book chapters

* **Lees JS**, Jardine AG. “Chapter 30: Cardiovascular Disease in Renal Transplantation”, Kidney Transplantation – Principles and Practice 8th Edition, Elsevier [2019]
* Shemilt R, **Lees JS**, Mark PB. “Chapter 30: Cardiovascular Disease in Renal Transplantation”, Kidney Transplantation – Principles and Practice 9th Edition, Elsevier [2024]

## Reports

Contributing author. “Time To Act: A New Review of Kidney Health Inequalities”. Kidney Research UK (2024).